PharmaFocus Today – media

Bodybuilding Linked To Sudden Cardiac Deaths

By Dennis Thompson HealthDay ReporterWEDNESDAY, May 21, 2025 (HealthDay News) — Bodybuilders spend countless hours in the gym to create a heart-stopping physique. But their efforts place their own hearts at risk of stopping, a new study says. Sudden cardiac death is responsible for an unusually high proportion of deaths in male bodybuilders, researchers reported today in the European Heart Journal. Further, professional bodybuilders are five times more likely to fall dead from cardiac arrest than amateurs, results show. “The risk of death among male bodybuilders is considerably high,” lead researcher Dr. Marco Vecchiato, a sports medicine specialist at the University of Padova in Italy, said in a news release. “Professional athletes had a markedly higher incidence of sudden cardiac death, suggesting that the level of competition might contribute to this increased risk.” The research was prompted by “a growing number of reports of premature deaths among people involved in ...
- Source: drugdu
- 45
- May 23, 2025
Deaths Waiting For Lung Donation Have Dropped Under New Guidelines

By Dennis Thompson HealthDay ReporterWEDNESDAY, May 21, 2025 (HealthDay News) — New guidelines for allocating donated lungs are saving more lives, a new study says. By prioritizing medical urgency, the guidelines caused a dramatic decline in the number of people who die waiting for a lung transplant, researchers reported Sunday at the American Thoracic Society’s international conference in San Francisco. Patients are now three times less likely to die on the waitlist than before 2017, when a lawsuit kicked off a rethinking of the way donated lungs were allocated, researchers say. The sickest patients on the waitlist saw the greatest benefit, researchers added. “We always want to make sure that any time we make a change to the allocation system that we’re improving outcomes, especially for our sickest patients,” lead researcher Dr. Mary Raddawi, a second-year pulmonary and critical care fellow at Columbia University Irving Medical Center, said in ...
- Source: drugdu
- 42
- May 23, 2025
InnoCare Pharma’s application for marketing approval of Tancitumomab for injection

On May 21, InnoCare Pharma (688428/09969) announced that the company received a notice from the National Medical Products Administration that the application for the marketing approval of tafasitamab combined with lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma was approved. This is the first CD19 monoclonal antibody approved in China to treat this disease, marking an important progress for the company in the field of hematological tumors. The announcement mentioned that Tancitumomab is a monoclonal antibody targeting CD19 and is suitable for adult patients who are not suitable for autologous stem cell transplantation. In addition, Tancitumomab combined with lenalidomide has also been approved for the treatment of eligible patients in Hong Kong, Macau and Taiwan, China, showing its potential for application in multiple regions. In the first quarter of 2025, InnoCare Pharma achieved revenue of 381 million yuan and net profit attributable to shareholders of the parent company ...
- Source: drugdu
- 43
- May 23, 2025
MicuRx Pharmaceuticals’ new drug application for contezolizumab sodium injection has been accepted

On May 21, Mengke Pharmaceuticals (688373) announced that the company’s new drug marketing authorization application for contezolidinone sodium for injection was accepted by the National Medical Products Administration. The drug is a Class 1 antibacterial drug of the oxazolidinone class independently developed by the company. The previous contezolidinone tablets were approved in 2021 for the treatment of complicated skin and soft tissue infections. The sodium contezolizumab for injection applied for this time is a water-soluble prodrug of contezolizumab. Based on the background that the prodrug has been approved, the company has carried out relevant Phase III clinical trials and successfully achieved the primary efficacy endpoint. Although the new drug marketing authorization application has been accepted, the announcement mentioned that the application still needs to go through review, clinical trial site inspection and approval, and the time and results are uncertain, so it will not have a significant impact on the ...
- Source: drugdu
- 41
- May 23, 2025
Pfizer acquires bispecific antibodies from 3SBio for $6.05 billion

On May 20, 3SBio announced that it had signed an exclusive licensing agreement with Pfizer, granting Pfizer the exclusive rights to develop, produce, and commercialize its independently developed breakthrough PD-1/VEGF bispecific antibody SSGJ-707 worldwide (excluding mainland China). At the same time, it retained the relevant rights of the product in mainland China and granted Pfizer the option to commercialize the product in mainland China. The total amount of this cooperation is as high as US$6.05 billion, including an upfront payment of US$1.25 billion and development, regulatory approval and sales milestone payments of up to US$4.8 billion. In addition, Pfizer will subscribe to 3SBio’s common stock worth US$100 million. SSGJ-707 is a bispecific antibody targeting PD-1/VEGF independently developed by 3SBio based on its proprietary #CLF2 platform. In the Phase II clinical phase analysis, it demonstrated excellent objective response rate (ORR) and disease control rate (DCR) in the treatment of patients with ...
- Source: drugdu
- 42
- May 23, 2025
Jingyin Pharmaceutical reached a 6.5 billion yuan cooperation

520, as the Internet Valentine’s Day, is deeply loved by couples. It has now become a popular day for pharmaceutical companies to officially announce cooperation. Today, a blockbuster news swept the entire pharmaceutical industry: Pfizer invested a huge amount of US$6.05 billion to introduce 3SBio’s PD-1/VEGF bispecific antibody SSGJ-707, marking another significant new milestone in China’s innovative drug overseas expansion – becoming the domestic license deal project with the highest down payment to date. However, amid this wave of attention, there is another innovative drug overseas collaboration that cannot be ignored today. That is the major collaboration between Jingyin Pharmaceutical and CRISPR Therapeutics. The two parties will work together to promote the development of innovative siRNA therapies, and the amount of this collaboration is as high as US$895 million (approximately RMB 6.5 billion). 6.5 billion yuan cooperation On May 20, Jingyin Pharmaceutical announced a strategic partnership with CRISPR Therapeutics, focusing ...
- Source: drugdu
- 37
- May 23, 2025
Changshan Pharmaceutical’s Nadroparin Calcium Injection Obtains Belarus Drug Registration Certificate

On May 20, Changshan Pharmaceutical(300255) announced that the company’s drug Nadroparin Calcium Injection has obtained the drug registration certificate issued by the Belarusian drug administration department. Nadroparin calcium injection is an injection with specifications of 0.4ml and 0.6ml. This drug is mainly used to treat moderate or high-risk venous thrombosis, prevent venous thromboembolic diseases, treat established deep vein thrombosis, and be used in combination with aspirin to treat unstable angina and acute stage of non-Q wave myocardial infarction; and prevent blood clot formation in extracorporeal circulation during hemodialysis. In the first quarter of 2025, Changshan Pharmaceutical achieved revenue of 259 million yuan and net profit attributable to shareholders of the parent company of 3.78 million yuan. https://finance.eastmoney.com/a/202505203409519560.html
- Source: drugdu
- 49
- May 22, 2025
Beihai Kangcheng’s Velaglucerase β for Injection is Approved for Marketing in China

Beihai Kangcheng announced that its independently developed injectable velaglucerase beta (Gorinin, CAN103) has been approved for marketing by the China National Medical Products Administration on May 15, 2025 for the treatment of type I and type III Gaucher disease. Gaucher disease is an autosomal recessive genetic disease caused by a deficiency of glucocerebrosidase, which leads to the accumulation of glucocerebroside in the body and causes a variety of symptoms. Gorenin is the first independently developed long-term enzyme replacement therapy in China suitable for adolescents aged 12 years and above and adults with type I and type III Gaucher disease. https://finance.eastmoney.com/a/202505203409423342.html
- Source: drugdu
- 49
- May 22, 2025
FDA filing is about to start, and one medical device has completed its first human clinical trial

Recently, Duke Herrell, CEO of Virtuoso Surgical, announced that the robotic endoscope system developed by the company has successfully completed the first batch of human clinical trials. This milestone event marks an important technological innovation in the field of minimally invasive surgery. It is reported that from May 12 to 13, the VIABLE clinical trial was performed by Professor Yuanjin Zhang of the Chinese University of Hong Kong, who successfully performed en bloc resection of bladder lesions on 6 patients, treating a total of 11 lesions. Professor Yuanjin Zhang is not only a top surgical expert in the field of bladder cancer, but also the pioneer of the “en-bloc” technique, which can significantly improve the completeness and accuracy of tumor resection. According to Virtuoso, the system is equipped with two needle-shaped robotic arms that pass through a sheath with a diameter of less than 1 cm and perform surgical operations ...
- Source: drugdu
- 44
- May 22, 2025
Phase I clinical drugs can bypass the FDA and go directly to market

Recently, the Montana legislature passed a bill that allows medical institutions to sell drugs that have only passed Phase I clinical trials without the need for U.S. FDA approval. The legislation was promoted by a group of people committed to extending human life span, including scientists, libertarians and opinion leaders. They hope that Montana can become a testing ground for medical innovation, providing more options for patients, especially those with terminal illnesses or those who are ineffective with existing treatments, so that they can have earlier access to some experimental drugs that may have potential therapeutic effects. What exactly does this bill include? First, doctors can apply for a license to open an experimental treatment clinic to recommend and sell non-FDA-approved therapies to patients. #No FDA approval required At the same time, these clinics must disclose all treatment effect and adverse event data to patients and regulators, and publish treatment ...
- Source: drugdu
- 43
- May 22, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.